Case Report

Intra-Abdominal Localisation of a Buschke-Lowenstein Tumour: Case Presentation and Review of the Literature

N. E. Wester, E. M. Hutten, C. Krikke, and Robert A. Pol

Division of Transplantation Surgery, Department of Surgery, University Medical Center Groningen, University of Groningen, P.O. Box 30 001, 9700 RB Groningen, The Netherlands

Correspondence should be addressed to Robert A. Pol; pol.chirurgie@gmail.com

Received 23 June 2013; Accepted 26 August 2013

Academic Editors: D. Capone, F. Keller, M. R. Moosa, and Y. Sugawara

Copyright © 2013 N. E. Wester et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Giant condyloma acuminatum or Buschke-Lowenstein tumour is a very rare disease which usually is located in the genital, anorectal, and perianal regions. It is regarded as a type of verrucous carcinoma occurring on anogenital mucosal surfaces where it is locally invasive but displays a benign cytology. We describe a case of a 24-year-old woman with persisting condyloma acuminata progressing to a large intra-abdominal Buschke-Lowenstein tumour. To our knowledge such an advanced stage has only been reported once before. The severity and extent of the tumour both determine the treatment and patient outcome. Treatment was impeded by cachexia, an immunosuppressive state after kidney transplantation and difficulties in establishing a reliable diagnosis. Interferon treatment was started which initially led to tumour reduction but was complicated by an interferon-induced pancreatitis, pneumonia, and fasciitis necroticans resulting in death. We present a literature overview on the treatment options for a Buschke-Lowenstein tumour, with emphasis on interferon therapy, with all the advantages and disadvantages.

1. Introduction

Worldwide prevalence of human papilloma virus (HPV) is 10%, mostly affecting women under the age of 35 [1]. The associated condylomata acuminata (CA) has an estimated prevalence of 0.75–3% in Europe and 1% in the United States [2]. One of the risk factors for CA is an immune-compromised state. On rare occasions progression to a Buschke-Lowenstein tumour (BLT) occurs. A BLT is a very rare, slowly growing, locally destructive, and infiltrative tumour associated with HPV types 6, 11, 16, and 18. Usually the tumour is located in the genital, anorectal, and perianal regions. Despite the benign histological characteristics of the tumour there is a high risk of recurrence and malignant transformation to squamous cell carcinoma (SCC), in particular for HPV types 16 and 18 [3–7]. Little is known about the true incidence rates of BLT due to the difficulties in histomorphological differentiation and thereby making the correct diagnosis. Current literature reports an increase to 6.3 cases per year in the last decade [8]. Due to this low incidence little is known about treatment outcomes, making comparison between various treatment regimens difficult.

To date only three papers are available reporting on, respectively, 42, 63, and 51 cases [3, 8, 9] and one small review [10]. They conclude that complete resection is the preferred initial therapy as it has the highest success rate and the lowest risk of recurrence. Contradictory is that surgery can be very mutilating as extensive resection is usually required due to ingrowth into local structures. Alternatively chemotherapy and radiation therapy have been described with varying results. However, in most cases, it proved to be difficult to determine a true malignancy so that there is a risk of overtreatment.

A possible alternative treatment may be interferon therapy as an effort to boost the patient’s own immune system [1–16]. As a new and experimental treatment for targeting BLT, there are no large series available let alone randomized trials. The majority of available data comes from other case reports and small case series concerning CA [17–20]. We present a rare case and provide a literature overview on the treatment options for a BLT, with emphasis on interferon therapy.

2. Case Presentation

A 24-year-old cachectic female patient, with a status after kidney transplantation due to hemolytic-uremic syndrome in 2000, was referred to our university medical center because
of persisting incapacitating CA under prolonged immunosuppressive therapy. Her initial immunosuppression regimen consisted of tacrolimus 5 mg and prednisolone 7.5 mg daily. At presentation in 2010 she suffered from severe CA located both intravaginal and perianal (Figure 1). This has led to excessive pain and defecation problems despite local and topical treatment by surgeons, gynaecologists, and dermatologists for over five years. Viral serology revealed the patient to be HPV-16 and HPV-18 positive. Her HIV status was negative. At our center multiple biopsies revealed serious dysplasia, and only one sample revealed malignant cells. Because of persistent lower back pain a MRI scan was performed. This showed a large process in the lower pelvic region with extension into the abdomen and cavum douglasi, consistent with the diagnosis intra-abdominal located BLT (Figure 2).

Prior to presentation at our hospital, the patient already had, in vain, several surgical procedures to obtain local control. At presentation both the cachexia of the patient, the localisation and infiltration of the process made surgical treatment (anterior and posterior exenteration) no realistic option. As a malignancy could not be definitely established, radio- or chemotheraphy was therefore not indicative. Because the tumour had centrally liquefied, resulting into abscesses, multiple drainage procedures were necessary. In order to treat the BLT the immunosuppressive therapy was lowered to 5 mg prednisone daily, and interferon therapy was started as an effort to boost the patients' immune system. After multidisciplinary consultation a dosage of 180 µg/week interferon alfa 2B was given by subcutaneous injections. After it became clear that the kidney function remained stable, the immunosuppressive therapy was further lowered to 5 and 2.5 mg prednisolone every other day. Because of severe malnutrition and cachexia, the patient received gastric tube feeding. During the interferon therapy a new abscess arose in the lower back, which was found to have a direct relationship with the BLT. On a follow-up MRI and CT scan, respectively, two and four months after the first interferon injection, a reduction in tumour mass was visible. As a chance finding an interferon-induced pancreatitis was visible on the CT. There were no further adverse effects of the therapy. Based on the established tumour reduction, interferon therapy was continued. Unfortunately after four months of treatment the patient was readmitted to our hospital because of a pneumococcal pneumonia for which antibiotic therapy was started. During hospitalization the patient developed progressive pain in the lower back and left leg in combination with a septic profile. The diagnosis necrotizing fasciitis was made and due to the clinical condition of the patient, combined with the extent of the disease, the treatment was discontinued in agreement with the family and the patient died. Unfortunately no informed consent was obtained for a postmortem examination.

3. Discussion

This report underlines the impact and difficulties of treating BLT. Progression to an intra-abdominal mass even further complicates treatment and to date has been described only once. Early detection of abdominal involvement in combination with a reliable histopathological diagnosis is essential for determining the appropriate treatment and predicting treatment outcome. When confronted with possible BLT it is very important to exclude an underlying malignancy. Other pelvic malignancies (gynaecological, gastrointestinal, and urological) should be considered, especially in younger women and patients with HPV types 16 and/or 18. In transplantation patients, posttransplant lymphoproliferative disorder should also be excluded, which was done in this patient and turned negative. In large BLTs possible sampling errors can make reliable detection of a malignancy difficult as they can contain malignant, premalignant, and/or benign cells. Also in our case only one biopsy sample revealed malignant cells. Repetitive biopsies were never able to definitely demonstrate true malignant transformation.

This report also shows that the choice of treatment is highly dependent on patient factors, such as cachexia and immune state in our patient. In this case abdominal involvement became apparent in an already advanced stage. With this paper we hope to create more awareness for the complexity of this disease and the considerations that must be taken.

A BLT is a rare condition, and, although the incidence appears to be increasing, there remains a lack of evidence on the appropriate steps to take in the treatment of these patients.
### Table 1: Literature overview of interferon therapy.

| Author (year of publication) | Patient characteristics | Tumour characteristics | Initial therapy (earlier surgical interventions Yes/No) | Interferon (IFN) therapy | Outcome |
|-----------------------------|-------------------------|------------------------|--------------------------------------------------------|--------------------------|---------|
|                             | Gender, age             | Comorbidity            | Tumours size (cm) | Location | HPV type | Followed by | Type | Way of administration | Dose | Frequency | Length | Adverse effects | |
| Tan et al. (2010) [15]      | F, 21                   | immuno-therapy (SLE)   | 15×7×3            | Vulvar    | 6        | Radical resection and IFN (Y) | none | — | — | 6 months | — | CR (2 years of follow-up) |
| Mudrikova et al. (2008) [10]| M, 44                   | HIV                    | —                 | Perineal and perianal | 6 | IFN + local cidofovir* (Y) | none | Pegylated | Subcutane | — | — | None | Pt died |
| De Toma et al. (2006) [21]  | M, 46                   | None                   | 8×6×6             | Perianal   | 6 | Surgical local excision** (N) | IFN | — | Systemic | 3 MU | — | — | CR (3 years of follow-up) |
| Antony et al. (2003) [11]   | M, 61                   | Therapy-resistant erythroderma | — | Perineum involving the penis | 16 | IFN* (N) | Chemo-therapy | α | Subcutane | 9 MU | 3/wk | — | Neutropenia - could be chemoinduced |
| Geusau et al. (2000) [12]   | M, 40                   | None                   | —                 | Perianal   | 6 | IFN (Y) | Partial chirurgic resection | α-2b | Intralesional | 10 MU | 3/wk | 28 months | — | CR after 12 m |
| Grassegger et al. (1994) [13]| M, 42                   | None                   | —                 | Genital/ perianal | 6 | Surgery (Y) | IFN | α-2c | Subcutane | 2 MU | 6/wk every 2nd wk | 3 months | — | Recurrence after 2 y |
| Tsambaos et al. (1994) [16] | M, 39                   | None                   | 8,7×7,3 ×5,6      | Inguinal   | 6, 11  | IFN* (N) | Podofyline | α-2b | Intralesional | 9 MU | 3/wk | — | Fever, myalgias, chills |
| Gritsch et al. (1989) [14]  | M, 29                   | None                   | 3,5 ×4           | Perianal   | — | IFN (Y) | Partial chirurgic resection | α | Subcutane | 6 MU | 7/wk | 30 days | — | CR after 5 months (16 months follow-up) |

(--): If not mentioned in article. * Patient refused surgery, ** Followed by radiotherapy and surgery, CR: Complete remission.
results are less favorable [3,33]. The detection or exclusion of disease sampling error can easily occur. Representative biopsy but can be very difficult to obtain. In an early stage of the malignant transformation is essential before initiating therapy as adjuvant therapy prior to surgery without chemoradiation as adjuvant therapy without surgery, and should be regarded as a last resort. Patient should be very thoroughly informed about the potential life-threatening risks.

Conflict of Interests
The authors declare no conflict of interests.

References
[1] S. de Sanjose, M. Diaz, X. Castellsague et al., “Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis,” Lancet Infectious Diseases, vol. 7, no. 7, pp. 453–459, 2007.
[2] C. S. Batista, A. N. Atallah, H. Saconato, and E. M. da Silva, “5-FU for genital warts in non-immunocompromised individuals,” Cochrane Database of Systematic Reviews, vol. 4, Article ID CD006562, 2010.
[3] Q. D. Chu, M. P. Vezeridis, N. P. Libbey, and H. J. Wanebo, “Giant condyloma acuminatum (Buschke-Lowenstein tumor) of the anorectal and perianal regions: analysis of 42 cases,” Diseases of the Colon and Rectum, vol. 37, no. 9, pp. 950–957, 1994.
[4] S. S. Ergün, Y. B. Kural, N. Büyükbabani, L. Verim, H. Akbulut, and L. Gürkan, “Giant condyloma acuminatum,” Dermatologic Surgery, vol. 29, no. 3, pp. 300–303, 2003.
[35] L. Risse, P. Negrier, P. M. Dang et al., “Treatment of verrucous carcinoma with recombinant alfa-interferon,” Dermatology, vol. 190, no. 2, pp. 142–144, 1995.

[36] S. Sleijfer, M. Bannink, A. R. Van Gool, W. H. J. Kruit, and G. Stoter, “Side effects of interferon-α therapy,” Pharmacy World and Science, vol. 27, no. 6, pp. 423–431, 2005.

[37] P. M. George, R. Badiger, W. Alazawi, G. R. Foster, and J. A. Mitchell, “Pharmacology and therapeutic potential of interferons,” Pharmacology and Therapeutics, vol. 135, pp. 44–53, 2012.

[38] C. Popescu, V. Arama, and S. Gliga, “Acute pericarditis due to pegylated interferon alpha therapy for chronic HCV hepatitis—case report,” BMC Gastroenterology, vol. 11, article 30, 2011.